Post-acute sequelae of SARS-CoV-2 associates with physical inactivity in a cohort of COVID-19 survivors

Imagem de Miniatura
Arquivos
art_GIL_Postacute_sequelae_of_SARSCoV2_associates_with_physical_inactivity_.PDF (1.18 MB)
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PORTFOLIO
Autores
ARAUJO, Adriana Ladeira de
Citação
SCIENTIFIC REPORTS, v.13, n.1, article ID 215, 8p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The aim of this study was to determine whether Post-acute Sequelae of SARS-CoV-2 Infection (PASC) are associated with physical inactivity in COVID-19 survivors. This is a cohort study of COVID-19 survivors discharged from a tertiary hospital in Sao Paulo, Brazil. Patients admitted as inpatients due to laboratory-confirmed COVID-19 between March and August 2020 were consecutively invited for a follow-up in-person visit 6 to 11 months after hospitalization. Ten symptoms of PASC were assessed using standardized scales. Physical activity was assessed by questionnaire and participants were classified according to WHO Guidelines. 614 patients were analyzed (age: 56 +/- 13 years; 53% male). Frequency of physical inactivity in patients exhibiting none, at least 1, 1-4, and 5 or more symptoms of PASC was 51%, 62%, 58%, and 71%, respectively. Adjusted models showed that patients with one or more persistent PASC symptoms have greater odds of being physically inactive than those without any persistent symptoms (OR: 1.57 [95% CI 1.04-2.39], P=0.032). Dyspnea (OR: 2.22 [1.50-3.33], P<0.001), fatigue (OR: 2.01 [1.40-2.90], P<0.001), insomnia (OR: 1.69 [1.16-2.49], P=0.007), post-traumatic stress (OR: 1.53 [1.05-2.23], P=0.028), and severe muscle/joint pain (OR: 1.53 [95% CI 1.08-2.17], P=0.011) were associated with greater odds of being physically inactive. This study suggests that PASC is associated with physical inactivity, which itself may be considered as a persistent symptom among COVID-19 survivors. This may help in the early identification of patients who could benefit from additional interventions tailored to combat inactivity (even after treatment of PASC), with potential beneficial impacts on overall morbidity/mortality and health systems worldwide.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/52830
Referências
  1. Andersson M, 2015, RESP MED, V109, P1048, DOI 10.1016/j.rmed.2015.05.007
  2. [Anonymous], 2020, NAT MED, V26, P1803, DOI 10.1038/s41591-020-01177-6
  3. Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
  4. Boonstra AM, 2014, PAIN, V155, P2545, DOI 10.1016/j.pain.2014.09.014
  5. Busatto GF, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-051706
  6. Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603
  7. Chekroud SR, 2018, LANCET PSYCHIAT, V5, P739, DOI 10.1016/S2215-0366(18)30227-X
  8. Damiano RF, 2022, GEN HOSP PSYCHIAT, V75, P38, DOI 10.1016/j.genhosppsych.2022.01.002
  9. Delbressine JM, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18116017
  10. Departamento de Analise em Saude e Vigilancia de Doencas nao Transmissiveis, 2020, VIG FAT RISC PROT DO
  11. Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
  12. Hamer M, 2019, PREV MED, V123, P65, DOI 10.1016/j.ypmed.2019.03.002
  13. Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
  14. Heesakkers H, 2022, JAMA-J AM MED ASSOC, V327, P559, DOI 10.1001/jama.2022.0040
  15. Heesch KC, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2154
  16. Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8
  17. IBGE, 2021, PESQUISA NACL AMOSTR
  18. Joffe M, 2012, EMERG THEMES EPIDEMI, V9, DOI 10.1186/1742-7622-9-1
  19. Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9
  20. Logue JK, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0830
  21. Lopez-Leon S, 2021, SCI REP-UK, V11, DOI [10.1038/s41598-021-95565-8, 10.1101/2021.01.27.21250617]
  22. Morin L, 2021, JAMA-J AM MED ASSOC, V325, P1525, DOI 10.1001/jama.2021.3331
  23. Morris G, 2019, PHARMACOL RES, V148, DOI 10.1016/j.phrs.2019.104450
  24. Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z
  25. Nasserie T, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.11417
  26. Paterson DH, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-38
  27. Pitta F, 2006, CHEST, V129, P536, DOI 10.1378/chest.129.3.536
  28. Reid RD, 2006, EUR J CARDIOV PREV R, V13, P529, DOI 10.1097/01.hjr.0000201513.13343.97
  29. Robins JM, 2001, EPIDEMIOLOGY, V12, P313, DOI 10.1097/00001648-200105000-00011
  30. Sheshadri A, 2019, KIDNEY INT REP, V4, P285, DOI 10.1016/j.ekir.2018.10.014
  31. Vale Francisco A.C., 2012, Dement. neuropsychol., V6, P212, DOI 10.1590/S1980-57642012DN06040004
  32. Weathers F., P 9 ANN M INT SOC TR
  33. Webster Kimberly, 2003, Health Qual Life Outcomes, V1, P79, DOI 10.1186/1477-7525-1-79
  34. Wong TL, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57050418
  35. Xie Y, 2022, NAT MED, V28, P583, DOI 10.1038/s41591-022-01689-3
  36. Zhao J, 2020, NEW ENGL J MED, V395, P497, DOI 10.1056/NEJMoa2002032
  37. ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - FM/MLS
Artigos e Materiais de Revistas Científicas - FM/MPS
Carregar mais